Our next question comes from the line of David Raso with Evercore ISI. Your line is now open.
Q – David Raso: Hi. Good morning. Quick question, the second quarter you have deliveries up 4%, but you're implying gross margins flat to down. Can you help explain that?
A – Ron Armstrong: Yeah. So, the truck margins are in the 12%, 12.5% range. First quarter the truck margins were 12.5%. So, a lot of the incremental revenue will come from the truck side. And so, that wading effect of trucks versus Parts, will sort of keep us in a similar range as to the first quarter.
Q – David Raso: Okay. Thank you. And then also, I noticed the CapEx increase, but you'll hold the R&D, or actually even tweaked it a little lower. And I am just trying to say -- this might be a question more for the meeting coming up in May. But, just trying to understand with all the new drivetrain technology and so forth, and for a long time people have always wondered, how the R&D as a percent of sales is so low for PACCAR. Can you help explain is there some capitalization of some of these dollars that maybe some people might think would be expenses R&D, can you just help us a little bit with the divergence between the CapEx increase and the R&D?
A – Ron Armstrong: Yeah. The CapEx increase is purely just as we've gotten into the year, the ability of our teams to move things forward has gone quicker than what we anticipated. Our plans are still pretty much the same. But we're actually going to be able to get things done quicker than what we'd originally anticipated. So, that's the capital increase. The R&D is, just part of how we prudently manage our product development efforts and have for years. We're probably going to spend a record amount of R&D for our company this year. But it's well thought out well positioned. And we feel good about we're doing everything we need to do to support the future needs for greenhouse gas changes, future products and also the advanced powertrain arena. So, I think we feel really good about what we're doing and the things that we're investing in both on the capital and R&D side.
Q – David Raso: Well, I think this is an important issue, because people are trying to figure out the cost pressures on the company with potentially some volume declines coming in the next year or two. So the divergence of -- we were able to pull things forward, and thus the CapEx goes up, but not the R&D?
A – Ron Armstrong: The R&D has gone up.
Q – David Raso: Can you help us understand a little better the – No. but the change, the change from the start of the year that caused the CapEx to go up hasn't had a commensurate increase in the R&D?
A – Ron Armstrong: Yeah because the plans and projects that we're working on hasn't changed, It's just the pace at which those capital projects are being executed, and the ability to get those done quicker than what we had originally anticipated. So, there was no change in the projects. It's just recognition of the timing of incurring those capital-related costs.
Q – David Raso: Can we -- I guess we can dive into this more in the May meeting. But I think the idea is sure if there's CapEx-related costs for the new introductions. The R&D has stayed at a relatively low level. And I think the ability to continue to do that the next couple of years or lack thereof is a big discussion around the earnings resiliency. So, I'll look forward to going to a little more detail in May.
A – Ron Armstrong: Sure. Okay.
Q – David Raso: Thank you very much. I appreciate it.
A – Ron Armstrong: Yeah. Thanks David.